Evidence map›Paper›PMID 37064613›Full record

ReviewNanotheranostics2023

Natural and synthetic nanovectors for cancer therapy.

Aziz Eftekhari, Carola Kryschi, David Pamies, Sukru Gulec, Elham Ahmadian, Dawid Janas, Soodabeh Davaran, Rovshan Khalilov

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Nanotheranostics, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 49 papers.

0numbers the graph read from it
0cells of the map it votes in
49citing papers in PubMed
17.8field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

49 citing papers in PubMed, 167 citations in OpenAlex.

  1. Review
  2. Article
  3. Nanoparticles in the Treatment of Renal Fibrosis.International journal of nanomedicine · 2026
    Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Review
  11. Review
  12. Review
  13. Article
  14. Article
  15. Review
  16. Article
  17. Review
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 7 institutions in 6 countries.

Aziz EftekhariDepartment of Biochemistry, Faculty of Science, Ege University, Izmir 35040, Turkey.
Carola KryschiDepartment of Chemistry and Pharmacy, Physical Chemistry I and ICMM, Friedrich-Alexander University of Erlangen─Nuremberg, Egerlandstrasse 3, D-91058 Erlangen, Germany.
David PamiesDepartment of Biomedical Sciences, University of Lausanne, Rue du Bugnon 7, 1005 Lausanne, Switzerland.
Sukru GulecMolecular Nutrition and Human Physiology Laboratory, Department of Food Engineering, İzmir Institute of Technology, 35430 Urla, İzmir, Turkey.
Elham AhmadianKidney Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
Dawid JanasDepartment of Organic Chemistry, Bioorganic Chemistry and Biotechnology, Silesian University of Technology, B. Krzywoustego 4, 44-100, Gliwice, Poland.
Soodabeh DavaranDepartment of Pharmaceutical Toxicology, Yeditepe University Faculty of Pharmacy, Istanbul, Turkey.
Rovshan KhalilovDepartment of Biophysics and Biochemistry, Baku State University, Baku, Azerbaijan.
Tabriz University of Medical Sciences · IRBaku State University · AZEge University · TRFriedrich-Alexander-Universität Erlangen-Nürnberg · DEIzmir Institute of Technology · TRSilesian University of Technology · PLUniversity of Basel · CH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Nanomaterials have been extensively studied in cancer therapy as vectors that may improve drug delivery. Such vectors not only bring numerous advantages such as stability, biocompatibility, and cellular uptake but have also been shown to overcome some cancer-related resistances. Nanocarrier can deliver the drug more precisely to the specific organ while improving its pharmacokinetics, thereby avoiding secondary adverse effects on the not target tissue. Between these nanovectors, diverse material types can be discerned, such as liposomes, dendrimers, carbon nanostructures, nanoparticles, nanowires, etc., each of which offers different opportunities for cancer therapy. In this review, a broad spectrum of nanovectors is analyzed for application in multimodal cancer therapy and diagnostics in terms of mode of action and pharmacokinetics. Advantages and inconveniences of promising nanovectors, including gold nanostructures, SPIONs, semiconducting quantum dots, various nanostructures, phospholipid-based liposomes, dendrimers, polymeric micelles, extracellular and exome vesicles are summarized. The article is concluded with a future outlook on this promising field.

Indexed as

DendrimersNanoparticlesNeoplasmsDrug Delivery SystemsHumansLiposomesDendrimersLiposomescancerdrug deliverynanomaterialsNanoparticlesnanovectors

Identifiers

PMID37064613
PMCPMC10093418
OpenAlexW4324009731

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.